Konakion

Phytomenadione, the active ingredient in Konakion, is a vitamin K presented as a sterile solution for intravenous and oral use. It is employed to correct vitamin K deficiency, reverse warfarin anticoagulation, and prevent hemorrhagic disease in newborns. It is indicated for patients of all ages, including neonates, and can be administered under medical supervision in hospital settings.

GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company follows stringent quality standards, offers full regulatory documentation, and provides reliable logistics for global distribution.

Konakion supplies the essential vitamin K1 cofactor to restore normal clotting in clinical situations where vitamin K deficiency or antagonism occurs.

- Vitamin K deficiency bleeding: restores clotting factor activity and reduces hemorrhage risk. - Warfarin reversal: rapidly replenishes vitamin K to counteract anticoagulant effect in emergency settings. - Neonatal hemorrhagic disease prophylaxis: given to newborns to prevent bleeding due to low vitamin K stores. - Antibiotic‑associated deficiency: supports clotting in patients on broad‑spectrum antibiotics that impair gut vitamin K synthesis.

Phytomenadione may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Nausea or vomiting: transient gastrointestinal upset. - Headache or dizziness: temporary central nervous system symptoms. - Flushing or warmth: short‑lasting sensation of heat.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention. - Hemolysis or severe anemia: rapid destruction of red blood cells. - Thromboembolic events: unexpected clot formation in vessels. - Elevated liver enzymes: significant hepatic enzyme rise indicating liver stress.

When using Konakion, several precautionary measures should be observed to ensure safety. - Assess vitamin K status: evaluate baseline coagulation parameters before administration. - Monitor coagulation: check INR or PT values regularly after dosing. - Use cautiously in liver disease: impaired synthesis may affect response. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Do not mix with incompatible IV solutions: verify compatibility before infusion. - Store at ambient temperature: keep in original container, protect from moisture and light.

Phytomenadione can interact with other medicines, influencing anticoagulant effects or vitamin K metabolism.

Major Interactions (Avoid): - Warfarin or other vitamin K antagonists: may reduce anticoagulant effect and require dose adjustment. - Concurrent high‑dose vitamin K preparations: risk of excessive clotting. - Broad‑spectrum antibiotics (e.g., cephalosporins): may alter gut flora and affect vitamin K levels, complicating therapy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: combined effect may increase thrombosis risk. - Heparin or low‑molecular‑weight heparin: additive anticoagulant effect may need monitoring. - Antifungal agents (e.g., fluconazole): can affect vitamin K metabolism enzymes. - Lipid‑lowering agents (statins): potential influence on vitamin K‑dependent pathways.